Optimum Methotrexate Exposure in Patients with Suspected or Confirmed CNS Invasive Hematological Malignancies: A Systematic Critical Review.

The major evidence found was that an MTX area under the curve (AUC) target between 1000 and 1100 μmol h-1 L is associated with better clinical outcomes. However, there appears to be a clinical gap in the prospective validation of HD and IT MTX management to optimize clinical outcomes and minimize toxicity, using the relationship between exposure level (AUC MTX) and optimal response to MTX, both at systemic and CNS exposure.